Foghorn Therapeutics is focusing on advancing its pipeline and strengthening its balance sheet through a recent equity financing. The company is highlighting progress in its clinical and preclinical programs, with several key milestones anticipated in 2026.
Strengthened balance sheet with $50 million equity financing, extending cash runway into the first half of 2028.
positiveFHD-909 Phase 1 dose-escalation trial for SMARCA4-mutant cancers is advancing as planned.
positiveSelective CBP degrader program on track to be IND-ready in 2026, with potential in ER+ breast cancer.
positiveSelective EP300 degrader program shows preclinical superior anti-tumor efficacy and tolerability, tracking to IND-enabling studies in 2026.
positiveThe company is clinical-stage and has not yet generated significant revenue, relying heavily on financing.
attentionProgression of pipeline programs is subject to significant clinical and regulatory risks.
attentionMargin metrics will be available once backend extracts data from insights_json
The company is pleased to have raised $50 million in an equity financing, priced at a 30% premium to the closing stock price.
This equity raise represents an important vote of confidence from key biotech investors in our vision and execution.
We continue to execute across our first-in-class pipeline focused on developing new treatment options for cancers with significant unmet need.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.